ライフサイエンスコーパス: semaglutide

1 ), REWIND (dulaglutide), and PIONEER 6 (oral semaglutide).

2 outcome that confirmed the noninferiority of semaglutide.

3 weekly for 24 weeks followed by 24 weeks off semaglutide.

4 ence of heterogeneity in the effects of oral semaglutide.

5 ne or in combination with the GLP-1 analogue semaglutide.

6 sus subcutaneous injection of GLP-1R agonist semaglutide.

7 nd reduced total cost by $33 583 relative to semaglutide.

8 iving tirzepatide and 4823 (52.5%) receiving semaglutide.

9 agonist semaglutide but are needed for oral semaglutide.

10 lutide or placebo were more common with oral semaglutide.

11 but nonsignificant percentage of patients on semaglutide 0.4 mg versus placebo achieving the secondar

12 The GLP-1R affinity of semaglutide (0.38 +/- 0.06 nM) was three-fold decreased

13 standard-care regimen to receive once-weekly semaglutide (0.5 mg or 1.0 mg) or placebo for 104 weeks.

14 o either once-weekly subcutaneously injected semaglutide (0.5 mg or 1.0 mg), or volume-matched placeb

15 All received subcutaneous semaglutide 1 mg weekly for 24 weeks followed by 24 week

16 2018, 788 patients were randomly assigned to semaglutide 1.0 mg (394 patients) or canagliflozin 300 m

17 1.73 m(2) (P(interaction)=0.06 and 0.008 for semaglutide 1.0 mg and liraglutide, respectively).

18 1.73 m(2) (P(interaction)=0.06 and 0.008 for semaglutide 1.0 mg and liraglutide, respectively).

19 eractive web response system to subcutaneous semaglutide 1.0 mg once weekly or oral canagliflozin 300

20 re enrolled and randomly assigned to receive semaglutide 1.0 mg or placebo (full analysis set), of wh

21 domly assigned (1:1) to receive subcutaneous semaglutide 1.0 mg or volume-matched placebo once weekly

22 Once-weekly semaglutide 1.0 mg was superior to daily canagliflozin 3

23 dent range, -0.7% to -1.9%) and subcutaneous semaglutide (-1.9%) and placebo (-0.3%); oral semaglutid

24 (1c) at week 26 was -1.2% (SE 0.1) with oral semaglutide, -1.1% (SE 0.1) with subcutaneous liraglutid

25 dication (128 0.5 mg semaglutide, 130 1.0 mg semaglutide, 129 placebo).

26 ast one dose of study medication (128 0.5 mg semaglutide, 130 1.0 mg semaglutide, 129 placebo).

27 an [SD] age 58.2 [10.8] years) received oral semaglutide 14 mg (n=536), 25 mg (n=535), or 50 mg (n=53

28 ported by 404 (76%) participants in the oral semaglutide 14 mg group, 422 (79%) in the 25 mg group, a

29 inical trials were identified-orlistat (22), semaglutide (14), liraglutide (11), tirzepatide (6), nal

30 was reported in 16 (13%) who received 0.5 mg semaglutide, 14 (11%) who received 1.0 mg semaglutide, a

31 17 (13%) of those assigned to 0.5 mg semaglutide, 16 (12%) assigned to 1.0 mg semaglutide, an

32 Adverse events were more frequent with semaglutide 2.4 mg (in 353 [87.6%] of 403 patients) and

33 Compared to placebo, patients treated with semaglutide 2.4 mg had lower rates of all-cause death, d

34 At week 68, more patients on semaglutide 2.4 mg than on placebo achieved weight reduc

35 Estimated treatment difference for semaglutide 2.4 mg versus placebo was -6.2 percentage po

36 ght reduction of at least 5% at 68 weeks for semaglutide 2.4 mg versus placebo, assessed by intention

37 baseline to week 68 was -9.6% (SE 0.4) with semaglutide 2.4 mg vs -3.4% (0.4) with placebo.

38 Concomitant treatment with cagrilintide and semaglutide 2.4 mg was well tolerated with an acceptable

39 ilintide, a long-acting amylin analogue, and semaglutide 2.4 mg, a glucagon-like peptide-1 analogue,

40 evidence synthesis of the following agents: semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topi

41 n=11) or placebo (n=24), in combination with semaglutide 2.4 mg, of whom 95 were exposed to treatment

42 ) ranged from 96.4 nmol/L to 120 nmol/L with semaglutide 2.4 mg.

43 4% [-12.8 to -2.1]), all in combination with semaglutide 2.4 mg.

44 mic events were reported in four patients on semaglutide (2.7%).

45 ed a 20-week run-in period with subcutaneous semaglutide, 2.4 mg once weekly, maintaining treatment w

46 iovascular and Other Long-term Outcomes with Semaglutide], -24%).

47 ive cagrilintide-semaglutide, 302 to receive semaglutide, 302 to receive cagrilintide, and 705 to rec

48 , with 2108 assigned to receive cagrilintide-semaglutide, 302 to receive semaglutide, 302 to receive

49 was reported in 26 (20%) who received 0.5 mg semaglutide, 31 (24%) who received 1.0 mg semaglutide, a

50 ng 41 222 adults meeting the study criteria (semaglutide, 32 029; tirzepatide, 9193), 18 386 remained

51 isted of 362 participants assigned to 0.5 mg semaglutide, 360 to 1.0 mg semaglutide, and 360 to insul

52 observation) of serious adverse events with semaglutide (43.23, 43.54, 51.07 and 47.06 for semagluti

53 Adverse events were more frequent with oral semaglutide 50 mg (307 [92%] of 334) than with placebo (

54 reduction of at least 5% at week 68 for oral semaglutide 50 mg versus placebo, assessed regardless of

55 was the most common adverse event with oral semaglutide (53 [21%]).

56 range, -2.1 kg to -6.9 kg) and subcutaneous semaglutide (-6.4 kg) vs placebo (-1.2 kg), and signific

57 m(2) (5.0) were randomly assigned to receive semaglutide (8803 [50.0%] patients) or placebo (8801 [50

58 rial, we compared the efficacy and safety of semaglutide (a GLP-1 receptor agonist) with canagliflozi

59 The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an

60 We assessed the efficacy and safety of semaglutide, a glucagon-like peptide-1 (GLP-1) analogue

61 A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist,

62 Oral semaglutide, a novel GLP-1 agonist, was compared with su

63 43% of participants (12 of 28) treated with semaglutide achieved low-risk HbA1c levels (<5.4%) vs 3%

64 8.17% (SD 0.89), at week 30, 0.5 and 1.0 mg semaglutide achieved reductions of 1.21% (95% CI 1.10-1.

65 45 kg (SD 21.79); at week 30, 0.5 and 1.0 mg semaglutide achieved weight losses of 3.47 kg (95% CI 3.

66 utide also confer cardiorenal benefits, with semaglutide additionally effective at reducing weight.

67 the glucagon-like peptide-1 receptor agonist semaglutide also confer cardiorenal benefits, with semag

68 peptide-1 receptor agonists liraglutide and semaglutide also reduced CV death and/or major adverse C

69 e -0.38% (95% CI -0.52 to -0.24) with 0.5 mg semaglutide and -0.81% (-0.96 to -0.67) with 1.0 mg sema

70 -4.62 kg (95% CI -5.27 to -3.96) with 0.5 mg semaglutide and -6.33 kg (-6.99 to -5.67) with 1.0 mg se

71 reported by 16 (4%) participants with 0.5 mg semaglutide and 20 (6%) with 1.0 mg semaglutide versus 3

72 maglutide (43.23, 43.54, 51.07 and 47.06 for semaglutide and 50.48, 49.66, 52.73 and 60.85 for placeb

73 g high BMI patients, approximately 58,000 on semaglutide and 66,000 on any GLP-1RA were compared to m

74 were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo.

75 , the pharmacokinetic parameters of released semaglutide and bodyweight loss were determined in mice,

76 Subcutaneous semaglutide and canagliflozin increased diabetic retinop

77 Odds of stroke were lower with subcutaneous semaglutide and dulaglutide.

78 th greater reductions (p < 0.05) compared to semaglutide and elafibranor.

79 ts occurred in 38 (10%) of 392 patients with semaglutide and in 20 (5%) of 394 patients with canaglif

80 n occurred in 2.9% of the patients receiving semaglutide and in 3.9% of those receiving placebo (haza

81 comorbid obesity/type 2 diabetes, the use of semaglutide and liraglutide were associated with a subst

82 d between November 2000 and August 2023 with semaglutide and liraglutide, respectively.

83 ieved in 81% vs 19% of patients treated with semaglutide and placebo, respectively (P < .001); improv

84 Although early trials of semaglutide and tirzepatide have shown promising results

85 rsus placebo (P < 0.0001), more than 10% for semaglutide and tirzepatide.

86 isenatide), LEADER (liraglutide), SUSTAIN 6 (semaglutide), and EXSCEL (extended-release exenatide).

87 (6 patients received liraglutide, 8 received semaglutide, and 1 received tirzepatide) and 4 received

88 mg semaglutide, 31 (24%) who received 1.0 mg semaglutide, and 10 (8%) who received placebo, and diarr

89 pants were randomly assigned to receive oral semaglutide, and 102 to receive placebo.

90 mg semaglutide, 16 (12%) assigned to 1.0 mg semaglutide, and 14 (11%) assigned to placebo discontinu

91 y, compared with 55 (15%) assigned to 1.0 mg semaglutide, and 26 (7%) assigned to insulin glargine.

92 ssigned to 0.5 mg semaglutide, 360 to 1.0 mg semaglutide, and 360 to insulin glargine.

93 ular efficacy for lixisenatide, liraglutide, semaglutide, and extended-release exenatide.

94 th 0.5 mg semaglutide, five (1%) with 1.0 mg semaglutide, and five (1%) with insulin glargine.

95 adverse events-mostly gastrointestinal with semaglutide, and others such as skin and subcutaneous ti

96 Antiobesity drugs orlistat, liraglutide, semaglutide, and phentermine-topiramate vs no treatment.

97 mg semaglutide, 14 (11%) who received 1.0 mg semaglutide, and three (2%) who received placebo.

98 Between baseline and 52 weeks, semaglutide attenuated progression of LA remodeling (est

99 ustained greater weight loss over 5 years vs semaglutide (BMI of 31.7 vs 33.0).

100 de and -6.33 kg (-6.99 to -5.67) with 1.0 mg semaglutide (both p<0.0001).

101 tide and -0.81% (-0.96 to -0.67) with 1.0 mg semaglutide (both p<0.0001).

102 the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.

103 One patient was assigned to semaglutide but was not treated (reason unknown).

104 on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in

105 gonist (dulaglutide, exenatide, liraglutide, semaglutide) classes.

106 y without diabetes, once-weekly subcutaneous semaglutide compared with once-daily subcutaneous liragl

107 rweight or obesity, once-weekly subcutaneous semaglutide compared with placebo, used as an adjunct to

108 4 mg once weekly, maintaining treatment with semaglutide compared with switching to placebo resulted

109 Use of oral semaglutide could potentially lead to earlier initiation

110 Data were unavailable for semaglutide, definitions of outcomes were heterogeneous,

111 49 (14%) participants assigned to 0.5 mg semaglutide discontinued treatment prematurely, compared

112 from baseline to week 26 decreased with oral semaglutide (dosage-dependent range, -0.7% to -1.9%) and

113 ctions in body weight were greater with oral semaglutide (dosage-dependent range, -2.1 kg to -6.9 kg)

114 placebo (-1.2 kg), and significant for oral semaglutide dosages of 10 mg or more vs placebo (dosage-

115 individualisation in clinical practice, oral semaglutide dose could be adjusted on the basis of presp

116 dication and renal function, to receive oral semaglutide (dose escalated to 14 mg once daily) or matc

117 on and country of origin, to once-daily oral semaglutide (dose escalated to 14 mg), once-daily subcut

118 er subcutaneous once-weekly 0.5 mg or 1.0 mg semaglutide (doses reached after following a fixed dose-

119 % CI, 0.31-0.82) analyses, but compared with semaglutide, dulaglutide had higher hazard of mortality

120 rticipants received once-weekly subcutaneous semaglutide during run-in.

121 used (lixisenatide, liraglutide, exenatide, semaglutide, efpeglenatide, dulaglutide, albiglutide, an

122 med steatosis and fibrosis received ALT-801, semaglutide, elafibranor, or vehicle daily for 12 weeks

123 Oral semaglutide, empagliflozin, and liraglutide also reduced

124 based background treatment (21 trials), oral semaglutide, empagliflozin, liraglutide, extended-releas

125 3.73 kg (95% CI -4.54 to -2.91) with 0.5 mg semaglutide (estimated treatment difference vs placebo -

126 ased by 4.53 kg (-5.34 to -3.72) with 1.0 mg semaglutide (estimated treatment difference vs placebo -

127 by 1.45% (95% CI -1.65 to -1.26) with 0.5 mg semaglutide (estimated treatment difference vs placebo -

128 reased by 1.55% (-1.74 to -1.36) with 1.0 mg semaglutide (estimated treatment difference vs placebo -

129 onal to cagrilintide dose and did not affect semaglutide exposure or elimination.

130 isenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide), EXSCEL (exenatide), Harmony Outcomes (albi

131 At 24 weeks, efinopegdutide (SUCRA: 67.02), semaglutide + firsocostat (SUCRA: 62.43), and pegbelferm

132 ported by two (<1%) participants with 0.5 mg semaglutide, five (1%) with 1.0 mg semaglutide, and five

133 retrospectively collected data on the use of semaglutide for adults with overweight or obesity betwee

134 ent randomization to either the cagrilintide-semaglutide group (904 patients) or the placebo group (3

135 eaths were reported: four (1%) in the 0.5 mg semaglutide group (three cardiovascular deaths, one panc

136 133 (82%) participants in the oral semaglutide group and 141 (88%) in the placebo group com

137 nts who underwent randomization (1767 in the semaglutide group and 1766 in the placebo group), median

138 were reported in 56 (37.3%) patients in the semaglutide group and 20 (13.2%) in the placebo group.

139 uses, 15 of 1591 patients (0.9%) in the oral semaglutide group and 30 of 1592 (1.9%) in the placebo g

140 739 patients completed the trial (367 in the semaglutide group and 372 in the canagliflozin group).

141 ed in 23 of 1591 patients (1.4%) in the oral semaglutide group and 45 of 1592 (2.8%) in the placebo g

142 uct occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo

143 ed in 61 of 1591 patients (3.8%) in the oral semaglutide group and 76 of 1592 (4.8%) in the placebo g

144 curred in 108 of 1648 patients (6.6%) in the semaglutide group and in 146 of 1649 patients (8.9%) in

145 was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo g

146 occurred in 6.7% of the participants in the semaglutide group and in 3.0% in the placebo group, with

147 ed in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%)

148 Five participants (4%) in the semaglutide group and no participants in the placebo gro

149 nts occurred in seven (4.7%) patients in the semaglutide group and six (4.0%) in the placebo group.

150 dsidered to be treatment related, one in the semaglutide group and two in the placebo group.

151 serious adverse events were reported in the semaglutide group compared with 301 in the placebo group

152 to 0.72]) were significantly reduced, in the semaglutide group compared with the placebo group (p<0.0

153 total of 95 of 131 participants (73%) in the semaglutide group had weight loss of 5% or more, as comp

154 in 197 (78%) of 253 participants in the oral semaglutide group versus 172 (69%) of 250 in the sitagli

155 drug, and 277 (97%) participants in the oral semaglutide group, 274 (96%) in the liraglutide group, a

156 Fewer serious adverse events occurred in the semaglutide group, although more patients discontinued t

157 ants in the CagriSema group, 22 (71%) in the semaglutide group, and 24 (80%) in the cagrilintide grou

158 were reported by 104 (69.3%) patients in the semaglutide group, and 247 adverse events were reported

159 81% (56 of 69 patients) in the subcutaneous semaglutide group, and 68% (48 of 71 patients) in the pl

160 3.1 events per 100 person-years) in the oral semaglutide group, as compared with 668 of the 4825 part

161 w or worsening nephropathy were lower in the semaglutide group, but rates of retinopathy complication

162 ly to be caused by treatment occurred in the semaglutide group.

163 of an adverse event, 13 of whom were in the semaglutide group.

164 t frequently reported adverse events in both semaglutide groups were gastrointestinal in nature: naus

165 63% to 86% (371 of 490 patients) in the oral semaglutide groups, 81% (56 of 69 patients) in the subcu

166 Patients given semaglutide had greater reductions in HbA(1c) (estimated

167 A lower proportion of patients treated with semaglutide had serious adverse events than did those wh

168 By use of the trial product estimand, oral semaglutide had significantly greater decreases in HbA(1

169 om overall baseline mean, patients receiving semaglutide had significantly greater reductions in HbA(

170 mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mi

171 Semaglutide has two amino acid substitutions compared to

172 Cagrilintide and semaglutide have each been shown to induce weight loss a

173 the incretin-based medicines tirzepatide and semaglutide have shown benefits in populations with vary

174 Finally, semaglutide improved physical QoL by 3.75 points on the

175 ly, it can assess the therapeutic effects of Semaglutide in a mouse model of diet-induced obesity.

176 d cardiovascular outcomes of once-daily oral semaglutide in an event-driven, randomized, double-blind

177 dosing and pharmacokinetics of the released semaglutide in humans.

178 investigate the efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderat

179 sment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and atherosc

180 iovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes [SUSTAIN-6]

181 Semaglutide is a glucagon-like peptide-1 (GLP-1) analogu

182 Semaglutide is a once-weekly glucagon-like peptide-1 (GL

183 Semaglutide is currently in phase 3 clinical testing.

184 A distinct advantage of TE-8105 over semaglutide is its low-dose reduction of liver steatosis

185 Oral semaglutide is the first oral formulation of a glucagon-

186 Oral semaglutide is the first oral glucagon-like peptide-1 (G

187 erved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-re

188 rticipants (89.0%) who reached the 2.4-mg/wk semaglutide maintenance dose were randomized (2:1) to 48

189 Collectively, these findings suggest that semaglutide may improve endogenous progenitor cell-media

190 Collectively, these data support semaglutide-mediated weight loss as a key treatment stra

191 Case studies, including semaglutide, MK-0616, LUNA18, sulanemadlin, and oxytocin

192 ed the efficacy, safety, and tolerability of semaglutide monotherapy, compared with placebo, in treat

193 Compared to usual care (n = 24), semaglutide (n = 22) led to a greater increase in the nu

194 (2:1) to 48 weeks of continued subcutaneous semaglutide (n = 535) or switched to placebo (n = 268),

195 d July 2024, 140 patients were randomized to semaglutide (n = 69) or standard therapy (n = 71).

196 were eligible and randomly assigned to oral semaglutide (n=163) or placebo (n=161).

197 Adverse events were more frequent with oral semaglutide (n=229 [80%]) and subcutaneous liraglutide (

198 were eligible and randomly assigned to oral semaglutide (n=253) or sitagliptin (n=251).

199 were eligible and randomly assigned to oral semaglutide (n=285), subcutaneous liraglutide (n=284), o

200 were randomly assigned to CagriSema (n=31), semaglutide (n=31), or cagrilintide (n=30).

201 most frequently reported adverse events with semaglutide, occurring in 184 (47%) of 392 patients; whe

202 1; double-blind) or once-weekly subcutaneous semaglutide of 1.0 mg (n = 70) for 26 weeks.

203 Once-daily oral semaglutide of 2.5 mg (n = 70), 5 mg (n = 70), 10 mg (n

204 nd a 2-way comparison of patients initiating semaglutide or dulaglutide between January 1, 2019, and

205 atients were recruited and randomized 1:1 to semaglutide or placebo (87 female participants (56.5%);

206 se-escalation schedule of 4 weeks of 0.25 mg semaglutide or placebo and 4 weeks of 0.5 mg semaglutide

207 se events leading to discontinuation of oral semaglutide or placebo were more common with oral semagl

208 ients were randomly assigned to receive oral semaglutide or placebo.

209 semaglutide or placebo and 4 weeks of 0.5 mg semaglutide or placebo.

210 adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and Septembe

211 e were 35 patients (0.04%) with NAION in the semaglutide or tirzepatide group and 19 patients (0.02%)

212 [52.15%]), including 79 699 patients in the semaglutide or tirzepatide group and 79 699 patients in

213 :1:1) to once-weekly subcutaneous CagriSema, semaglutide, or cagrilintide (all escalated to 2.4 mg).

214 t with a dual-labeled GLP-1 RA (liraglutide, semaglutide, or tirzepatide) between January 1, 2018, an

215 ate, top-dose phentermine and topiramate, or semaglutide over 13 months, 2 years, and 5 years among a

216 550) or no use (N = 2,983) and randomized to semaglutide/placebo.

217 once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a gr

218 ients, approximately 120,000 patients with a semaglutide prescription and 220,000 prescribed any GLP-

219 adults (>=18 years) who received an initial semaglutide prescription between January 1, 2018, and Ja

220 ompared outcomes of patients after the first semaglutide prescription with those of patients who had

221 Factors associated with incident semaglutide prescription within 6 months after obesity d

222 Cagrilintide-semaglutide provided significant and clinically relevant

223 ovy(R) formulation, whose main ingredient is semaglutide, received accelerated FDA approval in August

224 emaglutide (-1.9%) and placebo (-0.3%); oral semaglutide reductions were significant vs placebo (dosa

225 tly reported adverse events were nausea with semaglutide, reported in 77 (21%) patients with 0.5 mg a

226 Among patients with type 2 diabetes, oral semaglutide resulted in better glycemic control than pla

227 ERPRETATION: Compared with insulin glargine, semaglutide resulted in greater reductions in HbA1c and

228 pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions

229 Oral semaglutide resulted in superior weight loss (-4.4 kg [S

230 Causal mediation analysis assessed semaglutide's direct and indirect effects on Cognivue sc

231 lacebo (primary) and open-label subcutaneous semaglutide (secondary) on glycemic control in patients

232 ally, when insulin was used as a comparator, semaglutide showed a higher ROR for ION (ROR = 9.84, 95%

233 Compared to metformin, semaglutide showed increased reporting of optic ischemic

234 Semaglutide showed no increase in pancreas weight and no

235 Both tirzepatide and semaglutide showed normoglycemia restoration, remission

236 head-to-head comparison between MEDI7219 and semaglutide showed that MEDI7219 was more proteolyticall

237 INTERPRETATION: Semaglutide significantly improved HbA1c and bodyweight

238 ying these therapeutic effects revealed that semaglutide significantly increased levels of key neurop

239 Compared to placebo, PWH on semaglutide significantly increased visuospatial, naming

240 At week 26, semaglutide significantly reduced HbA1c level compared w

241 x (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more

242 from baseline to week 26 in bodyweight (oral semaglutide superiority vs placebo and liraglutide).

243 ge from baseline to week 26 in HbA(1c) (oral semaglutide superiority vs placebo and non-inferiority [

244 f Cardiovascular Ourcome Results], -13%) and semaglutide (SUSTAIN-6 trial [Trial to Evaluate Cardiova

245 se when compared with placebo in the case of semaglutide (SUSTAIN-6).

246 significantly lower among patients receiving semaglutide than among those receiving placebo, an outco

247 chieved an HbA(1c) of less than 7% with oral semaglutide than did with sitagliptin (treatment policy

248 More patients taking oral semaglutide than placebo had adverse events (120 [74%] o

249 s than 7% was significantly better with oral semaglutide than sitagliptin (treatment policy estimand:

250 -moderate nausea, were more common with oral semaglutide than with placebo.

251 om baseline to week 52 were higher with oral semaglutide than with sitagliptin (estimated mean change

252 week 26 was significantly greater with oral semaglutide than with subcutaneous liraglutide (-1.5 kg,

253 caemic drugs empagliflozin, liraglutide, and semaglutide-the latter being under review for approval b

254 Combined LA-LEAP2 and semaglutide therapy supports durable weight loss, addres

255 agnosis of eye disorders and were prescribed semaglutide, tirzepatide, or other antidiabetic medicati

256 Adding semaglutide to SGLT-2 inhibitor therapy significantly im

257 A few semaglutide-treated patients were hospitalized more freq

258 provement in MWD across sexes, which favored semaglutide treatment (P-interaction value = 0.65).

259 vary according to baseline diuretic use, and semaglutide treatment could modify diuretic dose.

260 n the STEP-HFpEF Program (pooled STEP-HFpEF [Semaglutide Treatment Effect in People with Obesity and

261 e with Obesity and HFpEF] and STEP-HFpEF DM [Semaglutide Treatment Effect in People with Obesity, HFp

262 nsistent trend for improved MWD that favored semaglutide treatment for both females and males (P inte

263 treatment-by-time interaction indicated that semaglutide treatment predicted greater relative reducti

264 reports of suicidal ideation associated with semaglutide treatment, a glucagon-like peptide 1 recepto

265 ficantly associated with MASH resolution and semaglutide treatment, with most related to metabolism a

266 the pancreas associated with liraglutide or semaglutide, two structurally different GLP-1 receptor a

267 e associated with the repeated high doses of semaglutide used in this study.

268 h 0.5 mg semaglutide and 20 (6%) with 1.0 mg semaglutide versus 38 (11%) with insulin glargine (p=0.0

269 wo cardiovascular outcome trials, SUSTAIN-6 (semaglutide versus sitagliptin as placebo proxy) and SUR

270 y weight change from baseline was -16.0% for semaglutide vs -5.7% for placebo (difference, -10.3 perc

271 (p=0.0021 and p=0.0202 for 0.5 mg and 1.0 mg semaglutide vs insulin glargine, respectively).

272 A higher proportion of participants in the semaglutide vs placebo group achieved weight losses of a

273 of reduction in bodyweight was similar with semaglutide vs placebo regardless of baseline NYHA funct

274 ed treatment difference [ETD] range for oral semaglutide vs placebo, -0.4% to -1.6%; P = .01 for 2.5

275 er serious adverse events were reported with semaglutide vs placebo.

276 the KCCQ-CSS and 6MWD, and levels of CRP in semaglutide- vs placebo-treated patients.

277 er weight loss (18 RCTs; 6321 participants), semaglutide was associated with 11.4% greater weight los

278 nic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower ri

279 At 208 weeks, semaglutide was associated with mean reduction in weight

280 Oral semaglutide was effective in patients with type 2 diabet

281 a head-to-head comparison of tirzepatide and semaglutide was implemented.

282 Oral semaglutide was non-inferior to subcutaneous liraglutide

283 Oral semaglutide was non-inferior to subcutaneous liraglutide

284 tes, the cardiovascular risk profile of oral semaglutide was not inferior to that of placebo.

285 Semaglutide was selected as the optimal once weekly cand

286 At 26 weeks, oral semaglutide was superior to placebo in decreasing HbA(1c

287 Although tirzepatide and semaglutide were shown to reduce weight in randomized cl

288 Safety and tolerability of oral semaglutide were similar to subcutaneous liraglutide.

289 ed to investigate the efficacy and safety of semaglutide when added to SGLT-2 inhibitor therapy in pa

290 cally stable (% remaining after 90 min) than semaglutide, which was degraded completely within 10 min

291 CagriSema (semaglutide with cagrilintide) resulted in the highest w

292 se-lowering medication at screening, to oral semaglutide with flexible dose adjustments to 3, 7, or 1

293 To compare the effects of oral semaglutide with placebo (primary) and open-label subcut

294 A comparison of semaglutide with real-world proteomic profiles revealed

295 h tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and

296 safety of flexible dose adjustments of oral semaglutide with sitagliptin 100 mg.

297 Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrili

298 sed a Markov cohort model to compare ESG and semaglutide, with a no-treatment baseline strategy.

299 Oral semaglutide, with flexible dose adjustment, based on eff

300 We hypothesized that semaglutide would be noninferior to placebo for the prim